This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of 4.55% and 3.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?
by Ekta Bagri
AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now.
AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for March 5th
by Zacks Equity Research
PFLT, COMM, BGC, NLY and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on March 5, 2025.
CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?
by Zacks Equity Research
On CTMX's fourth-quarter 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.
Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU)
by Zacks Equity Research
The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
New Strong Buy Stocks for January 31st
by Zacks Equity Research
ENS, SOPA, MC, SFIX and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of -159.52% and 99.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
by Zacks Equity Research
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
by Zacks Equity Research
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
by Kinjel Shah
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
by Zacks Equity Research
Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
by Zacks Equity Research
The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.
Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does AC Immune (ACIU) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Small-Cap Stocks to Play the January Effect
by Sweta Killa
Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.
AC Immune (ACIU) Upgraded to Buy: Here's Why
by Zacks Equity Research
AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity
by Zacks Equity Research
Biogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog.
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
by Ekta Bagri
The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.
Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and AC Immune (ACIU) have performed compared to their sector so far this year.
Are Medical Stocks Lagging AC Immune (ACIU) This Year?
by Zacks Equity Research
Here is how AC Immune (ACIU) and Exact Sciences (EXAS) have performed compared to their sector so far this year.
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AC Immune (ACIU) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.